Literature DB >> 30292432

Bridge to recovery in children on ventricular assist devices-protocol, predictors of recovery, and long-term follow-up.

Oliver Miera1, Matthias Germann2, My Y Cho3, Joachim Photiadis3, Eva M Delmo Walter4, Roland Hetzer5, Felix Berger6, Katharina R L Schmitt7.   

Abstract

BACKGROUND: The majority of children supported with ventricular assist devices (VADs) are bridged to heart transplantation. Although bridge to recovery has been reported, low recovery patient numbers has precluded systematic analysis. The aim of this study was to delineate recovery rates and predictors of recovery and to report on long-term follow-up after VAD explantation in children.
METHODS: Children bridged to recovery at our institution from January 1990 to May 2016 were compared with a non-recovery cohort. Clinical and echocardiographic data before and at pump stoppages and after VAD explantation were analyzed. Kaplan‒Meier estimates of event-free survival, defined as freedom from death or transplantation after VAD removal, were determined.
RESULTS: One hundred forty-nine children (median age 5.8 years) were identified. Of these, 65.2% had cardiomyopathy, 9.4% had myocarditis, and 24.8% had congenital heart disease. The overall recovery rate was 14.2%, and was 7.1% in patients with dilated cardiomyopathy. Predictors of recovery were age <2 years (recovery rate 27.8%, odds ratio [OR] 5.64, 95% confidence interval [CI] 2.0 to 16.6) and diagnosis of myocarditis (rate 57.1%; OR 17.56, 95% CI 4.6 to 67.4). After a median follow-up of 10.8 years, 15 patients (83.3%) were in Functional Class I and 3 (16.7%) in were in Class II. Mean left ventricular ejection fraction was 53% (range 28% to 64%). Ten- and 15-year event-free survival rates were both 84.1 ± 8.4%.
CONCLUSIONS: Children <2 years of age and those diagnosed with myocarditis have the highest probability of recovery. Long-term survival after weaning from the VAD was better than after heart transplantation, as demonstrated in the excellent long-term stability of ejection fraction and functional class.
Copyright © 2018 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  children; device explantation; heart failure; myocardial recovery; risk factors; survival; ventricular assist device

Mesh:

Year:  2018        PMID: 30292432     DOI: 10.1016/j.healun.2018.08.005

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  5 in total

Review 1.  Pediatric Myocarditis: What Have We Learnt So Far?

Authors:  Elettra Pomiato; Marco Alfonso Perrone; Rosalinda Palmieri; Maria Giulia Gagliardi
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-03

2.  Heart failure in the young: Insights into myocardial recovery with ventricular assist device support.

Authors:  Eva Maria Javier Delmo; Mariano Francisco Del Maria Javier; Dietmar Böthig; Andre Rüffer; Robert Cesnjevar; Michael Dandel; Roland Hetzer
Journal:  Cardiovasc Diagn Ther       Date:  2021-02

3.  Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.

Authors:  Shi Shen; Lorenzo R Sewanan; Stuart G Campbell
Journal:  J Mol Cell Cardiol       Date:  2021-05-14       Impact factor: 5.763

4.  Short-term outcomes of EXCOR Paediatric implantation.

Authors:  Motoki Komori; Takaya Hoashi; Heima Sakaguchi; Kenta Imai; Naoki Okuda; Norihide Fukushima; Kenichi Kurosaki; Hajime Ichikawa
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

5.  Pathogenic Variants Associated With Dilated Cardiomyopathy Predict Outcome in Pediatric Myocarditis.

Authors:  Jirko Kühnisch; Sabine Klaassen; Franziska Seidel; Manuel Holtgrewe; Nadya Al-Wakeel-Marquard; Bernd Opgen-Rhein; Josephine Dartsch; Christopher Herbst; Dieter Beule; Thomas Pickardt; Karin Klingel; Daniel Messroghli; Felix Berger; Stephan Schubert
Journal:  Circ Genom Precis Med       Date:  2021-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.